Eli Lilly and Company (LLY) fair value analysis
S&P 500 · Updated 2026-10-19
LLY price how computed
Forward Fair Value verdict
UndervaluedLLY is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $1,179.27
- Sector
- Healthcare
- 12-month range
- $813.53–$1,280.34
- Market cap
- $1.05T
- From 52-week high
- -7.9%
- Shares outstanding
- 892M
- Rank in Healthcare by discount to fair value
- #9 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Eli Lilly and Company is a pharmaceutical company that discovers, develops, manufactures, and sells medications for various therapeutic areas including oncology, immunology, endocrinology, and neuroscience. The company operates globally with operations and presence across multiple continents including North America, Europe, Asia, and other regions worldwide.
LLY currently ranks #9 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $1.05T
- P/E (trailing)
- 37x
- Revenue (TTM)
- $79.7B
- Net margin
- 33.5%
- EPS (TTM)
- $31.49
- Gross margin
- 85.8%
- Debt / equity
- 1.62
- Revenue growth (3-yr avg)
- 47.3%
- Shares outstanding
- 892M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 71 · overbought
- 50-day average
- $1,180.35
- 200-day average
- $1,079.91
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
- Momentum score
- 70 · grade B
- Positive weeks (of 12)
- 3
Dividends how computed
- Paid, last 12 months
- $6.69 per share (4 payments)
- Yield on last price
- 0.57%
- Consecutive years of increases
- 11
- Last ex-dividend date
- 2026-08-14
- Last payment date
- 2026-09-10
Earnings how computed
- Next earnings report
- 2026-10-29 (pre-market)
- Last 8 quarters vs consensus
- 6 beat, 2 missed
- Quarter by quarter
- 2026-06 ▲ beat (+39.4%)
2026-03 ▲ beat (+25.9%)
2025-12 ▲ beat (+5.2%)
2025-09 ▲ beat (+19.2%)
2025-06 ▲ beat (+12.5%)
2025-03 ▼ miss (-3.5%)
2024-12 ▲ beat (+5.0%)
2024-09 ▼ miss (-19.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 25 buy · 3 hold · 2 sell (30 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $1330
- Target vs last price
- +12.8%
What our data shows for LLY
- Our model validated 16 trailing price-to-earnings windows for LLY, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $813.53–$1,280.34.
- The 14-day relative strength index sits at an overbought 71.
- 3 of the last 12 weekly snapshots showed positive price momentum.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for LLY
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent LLY news
TickrTrends' derived news-sentiment signal for LLY is currently leaning positive, computed from recent coverage.
- Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know (zacks.com, 2026-10-21)
TickrTrends take: Eli Lilly and Company operates in the Healthcare sector and currently carries an Undervalued designation according to TickrTrends valuation metrics. The elevated investor search activity noted in recent reports may reflect growing market interest in the company's fundamentals relative to its current valuation standing. For valuation-focused readers, this combination of undervaluation status and heightened investor attention warrants monitoring whether the market will eventually price the company's assets and earnings potential more fully. - Eli Lilly (LLY) Pursues Pediatric Approval for Omvoh After Positive Ulcerative Colitis Trial (gurufocus.com, 2026-10-19)
TickrTrends take: Eli Lilly's advancement of Omvoh toward pediatric indications follows positive clinical results in ulcerative colitis, potentially expanding the drug's addressable market beyond current approved populations. TickrTrends currently assesses LLY as undervalued within the Healthcare sector, and successful pediatric approval could strengthen the revenue growth narrative that supports this valuation view. Investors focused on valuation metrics should monitor clinical progression timelines and eventual label expansion announcements, as these outcomes could influence the company's long-term earnings potential and justify current pricing. - METiS TechBio Partners with Eli Lilly (LLY) to Advance Lipid Nanoparticle Delivery Systems (gurufocus.com, 2026-10-19)
TickrTrends take: LLY's partnership with METiS TechBio on lipid nanoparticle delivery systems represents a strategic investment in drug delivery infrastructure that could expand the company's pipeline capabilities across multiple therapeutic areas. Given TickrTrends' current undervalued assessment, investors focused on valuation should monitor whether this collaboration produces meaningful clinical advancement or revenue contributions that might justify current market pricing. The partnership's success in improving delivery efficacy could become a differentiating factor for LLY's competitive positioning in the Healthcare sector, particularly if it accelerates development timelines for pipeline candidates.
More LLY news
- Eli Lilly (LLY) Reports Positive Phase 3 SHINE-2 Trial Results for Pediatric Ulcerative Colitis (gurufocus.com, 2026-10-19)
- Eli Lilly’s Growth Is Exceptional. Is Its Valuation Asking Too Much? (insidermonkey.com, 2026-10-16)
- EMA Endorses Eli Lilly's Foundayo for Type 2 Diabetes; LLY Stock Shows 20% Undervaluation (gurufocus.com, 2026-10-16)
- Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock (zacks.com, 2026-10-09)
- Novo Nordisk (NVO) or Eli Lilly (LLY)? Jim Cramer Gives a Clear Response (insidermonkey.com, 2026-10-08)
- Foundayo Showed Better Results Than Oral Semaglutide in a New Analysis. There’s a Catch Investors Shouldn’t Miss (insidermonkey.com, 2026-10-06)
What people are saying
Follow the LLY conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for LLY showed notable shifts this week. Momentum moved from none to a B rating, while the Relative Strength Index zone transitioned from neutral to overbought. The stock maintains an undervalued valuation verdict according to TickrTrends' assessment.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — LLY's RSI zone improved this week, moving from oversold conditions to neutral territory, suggesting reduced downward momentum in the Healthcare sector stock. The company maintains an undervalued status according to TickrTrends' derived indicators, indicating potential opportunity for investors monitoring the sector.
- 2026-09-21 — LLY's relative strength index moved from the neutral zone into oversold territory this week, indicating that recent selling pressure has intensified. The stock remains classified as undervalued based on TickrTrends' derived valuation metrics within the Healthcare sector.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is LLY stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), LLY is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is LLY's TickrTrends verdict?
LLY's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does LLY compare to other Healthcare stocks?
LLY ranks #9 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is LLY overbought or oversold?
LLY's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.
Does LLY pay a dividend?
Yes. LLY paid $6.69 per share over the last twelve months (4 payments), a 0.57% yield on TickrTrends' last price, and has raised the annual total for 11 consecutive years. The last ex-dividend date was 2026-08-14.
When does LLY report earnings next?
LLY's next earnings report is scheduled for 2026-10-29 (pre-market), per the published earnings calendar.
Does LLY usually beat earnings estimates?
Over its last 8 reported quarters LLY beat the consensus estimate 6 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about LLY?
Of 30 analysts covering LLY, 25 rate it a buy, 3 a hold and 2 a sell - buy-leaning, with a consensus price target of $1330 (+12.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
LLY vs ALGN · LLY vs ANIP · LLY vs COLL · LLY vs COO · LLY vs DXCM